Free Trial

ARCA biopharma Q4 2023 Earnings Report

ARCA biopharma EPS Results

Actual EPS
-$11.52
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ARCA biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ARCA biopharma Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

24/7 Automated Profits in Crypto (Ad)

What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.

>> Secure Your Spot On The Groundbreaking Workshop Here

ARCA biopharma Earnings Headlines

First JFK… next Elon?
Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
See More ARCA biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ARCA biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ARCA biopharma and other key companies, straight to your email.

About ARCA biopharma

ARCA biopharma (NASDAQ:ABIO), a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

View ARCA biopharma Profile

More Earnings Resources from MarketBeat